GLORIA — GEOMAR Library Ocean Research Information Access

Hits per page

hit 1 - 1 | 1 hit

Sorting

Unknown

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein [Vaccines and Antiviral Agents] (2015)

Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., Schmidt, J., Becker, C., Eickmann, M., Becker, S., Sutter, G.

The American Society for Microbiology (ASM)

In: Journal of Virology

add to mindlist on the mindlist

Details

Publication Date: 2015-07-22

Description: Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory disease in humans. We tested a recombinant modified vaccinia virus Ankara (MVA) vaccine expressing full-length MERS-CoV spike (S) glycoprotein by immunizing BALB/c mice with either intramuscular or subcutaneous regimens. In all cases, MVA-MERS-S induced MERS-CoV-specific CD8 + T cells and virus-neutralizing antibodies. Vaccinated mice were protected against MERS-CoV challenge infection after transduction with the human dipeptidyl peptidase 4 receptor. This MERS-CoV infection model demonstrates the safety and efficacy of the candidate vaccine.

Print ISSN: 0022-538X

Electronic ISSN: 1098-5514

Topics: Medicine

Published by The American Society for Microbiology (ASM)

Permalink

	Location	Call Number	Limitation	Availability

Others were also interested in ...

PAPER CURRENT

Fulltext

hit 1 - 1 | 1 hit